<DOC>
	<DOCNO>NCT02897778</DOCNO>
	<brief_summary>The purpose study evaluate effect entinostat heart rate electrocardiogram parameter . This study also evaluate safety tolerability entinostat , well pharmacokinetic pharmacodynamic parameter .</brief_summary>
	<brief_title>Cardiac Safety Study Entinostat Men Women With Advanced Solid Tumors</brief_title>
	<detailed_description>This single center , randomize , placebo-controlled , single dosing schedule , double-blinded study evaluate effect entinostat compare placebo electrical activity heart patient advance solid tumor . Thirty patient randomize 1:1 ratio receive either entinostat placebo . Study treatment blind patient Investigator . ECG analyst blind patient , visit , treatment allocation . Patients study 30 day follow study drug administration . Total study duration expect 9 month . After complete study discretion Investigator , patient may elect enroll separate continuation study ( SNDX-275-0141 ) .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Breast Diseases</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Neoplasms Histologic Type</mesh_term>
	<mesh_term>Thoracic Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Respiratory Tract Neoplasms</mesh_term>
	<mesh_term>Bronchial Neoplasms</mesh_term>
	<mesh_term>Endocrine Gland Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<mesh_term>Entinostat</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis solid tumor malignancy responsive standard therapy ( y ) approve therapy Patients must acceptable laboratory requirement Left ventricular ejection fraction measure echocardiogram multiplegated acquisition scan institutional low level normal great 50 % Has experience resolution toxic effect ( ) recent prior chemotherapy and/or prior surgical radiation treatment Must able understand give write informed consent comply study procedure If patient brain metastasis , must stable neurologic status without use steroid stable decrease dose steroid Presence clinically significant gastrointestinal abnormality may affect absorption study treatments A medical condition precludes adequate study treatment compliance assessment , increase patient risk opinion Investigator Patient concomitant cardiovascular issue precludes adequate study treatment compliance increase patient risk Diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study drug Prior chemotherapy , target small molecule therapy , radiation therapy within 4 week prior study Prior anticancer monoclonal antibody within 4 week prior baseline Currently enrol another investigational study Has disease suitable approve therapy administer curative intent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>entinostat</keyword>
	<keyword>solid tumor</keyword>
	<keyword>Histone Deacetylase Inhibitors</keyword>
</DOC>